{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:46:03Z","timestamp":1786121163886,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejphar.2026.178639","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T17:08:42Z","timestamp":1770311322000},"page":"178639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety, pharmacokinetics, and sex hormone suppression of LY01021 versus relugolix: A single- and multiple-dose escalation study"],"prefix":"10.1016","volume":"1017","author":[{"given":"Yafen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Lei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5930-586X","authenticated-orcid":false,"given":"Guo-Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178639_bib1","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","volume":"4","author":"Al-Inany","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2026.178639_bib2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40265-024-02018-3","article-title":"Relugolix\/Estradiol\/Norethisterone acetate: a review in endometriosis-associated pain","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2026.178639_bib3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0022-4731(85)80003-0","article-title":"GnRH receptors and actions in the control of reproductive function","volume":"23","author":"Catt","year":"1985","journal-title":"J. Steroid Biochem."},{"key":"10.1016\/j.ejphar.2026.178639_bib4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.tem.2020.07.002","article-title":"The sex bias of cancer","volume":"31","author":"Costa","year":"2020","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.ejphar.2026.178639_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1051\/rnd:2005017","article-title":"Gonadotropin-releasing hormone and the control of gonadotrope function","volume":"45","author":"Counis","year":"2005","journal-title":"Reprod. Nutr. Dev."},{"key":"10.1016\/j.ejphar.2026.178639_bib6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1208\/s12249-020-01776-z","article-title":"Assessment of dose proportionality of Rivaroxaban nanocrystals","volume":"21","author":"Demir","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejphar.2026.178639_bib7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1472-6483(10)60945-5","article-title":"Extrapituitary effects of GnRH antagonists in assisted reproduction: a review","volume":"10","author":"Engel","year":"2005","journal-title":"Reprod. Biomed. Online"},{"key":"10.1016\/j.ejphar.2026.178639_bib8","first-page":"Cd010537","article-title":"Assisted reproductive technology: an overview of Cochrane reviews","volume":"8","author":"Farquhar","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2026.178639_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2165\/00003495-200464060-00001","article-title":"Gonadotropin-releasing hormone antagonists for assisted reproductive techniques: are there clinical differences between agents?","volume":"64","author":"Griesinger","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2026.178639_bib10","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-Dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-Small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2026.178639_bib11","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1080\/14796694.2025.2480050","article-title":"Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US","volume":"21","author":"Hafron","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejphar.2026.178639_bib12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/pst.326","article-title":"Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion","volume":"8","author":"Hummel","year":"2009","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.ejphar.2026.178639_bib13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/humupd\/dmv016","article-title":"Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century","volume":"21","author":"Inhorn","year":"2015","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.ejphar.2026.178639_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2024.108137","article-title":"CPhaMAS: an online platform for pharmacokinetic data analysis based on optimized parameter fitting algorithm","volume":"248","author":"Kuang","year":"2024","journal-title":"Comput. Methods Progr. Biomed."},{"key":"10.1016\/j.ejphar.2026.178639_bib15","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40262-023-01269-9","article-title":"A randomized open-label study of relugolix alone or relugolix combination therapy in premenopausal women","volume":"62","author":"Lukes","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2026.178639_bib16","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1210\/jc.2015-2770","article-title":"Medical castration using the investigational oral GnRH antagonist TAK-385 (Relugolix): phase 1 study in healthy males","volume":"100","author":"MacLean","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2026.178639_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040647","article-title":"Progesterone actions and resistance in gynecological disorders","volume":"11","author":"MacLean","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2026.178639_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/clpt.2011.108","article-title":"Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study","volume":"90","author":"Maeda","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2026.178639_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0889-8529(18)30286-X","article-title":"Pubertal growth and growth hormone secretion","volume":"20","author":"Martha","year":"1991","journal-title":"Endocrinol Metab. Clin. N. Am."},{"key":"10.1016\/j.ejphar.2026.178639_bib20","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1093\/humrep\/13.11.3023","volume":"13","year":"1998","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.ejphar.2026.178639_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ph18010036","article-title":"GnRH peptide antagonist: comparative analysis of chemistry and formulation with implications for clinical safety and efficacy","volume":"18","author":"Patel","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2026.178639_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12672-015-0238-x","article-title":"Metabolic syndrome and prostate cancer: a review of complex interplay amongst various endocrine factors in the pathophysiology and progression of prostate cancer","volume":"7","author":"Rhee","year":"2016","journal-title":"Horm Cancer"},{"key":"10.1016\/j.ejphar.2026.178639_bib23","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1126\/science.173.4001.1036","article-title":"Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones","volume":"173","author":"Schally","year":"1971","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2026.178639_bib24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s10815-012-9812-0","article-title":"Does the degree of hypothalamic-pituitary-ovarian recovery after oral contraceptive pills affect outcomes of IVF\/ICSI cycles receiving GnRH-antagonist adjuvant therapy in women over 35 years of age?","volume":"29","author":"Schmitz","year":"2012","journal-title":"J. Assist. Reprod. Genet."},{"key":"10.1016\/j.ejphar.2026.178639_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/pcan.2012.25","article-title":"New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists","volume":"16","author":"Shore","year":"2013","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ejphar.2026.178639_bib26","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178639_bib27","year":"2025"},{"key":"10.1016\/j.ejphar.2026.178639_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.beem.2007.09.002","article-title":"Ontogeny of gonadal sex steroids","volume":"22","author":"Svechnikov","year":"2008","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.ejphar.2026.178639_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa1700089","article-title":"Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist","volume":"377","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178639_bib30","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.eururo.2009.11.029","article-title":"Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics","volume":"57","author":"Tombal","year":"2010","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2026.178639_bib31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrendo.2013.255","article-title":"Endometriosis: pathogenesis and treatment","volume":"10","author":"Vercellini","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejphar.2026.178639_bib32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.14740\/jocmr6236","article-title":"Oral gonadotropin-releasing hormone antagonists in the treatment of endometriosis: advances in research","volume":"17","author":"Wang","year":"2025","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.ejphar.2026.178639_bib33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/1471-0528.14966","article-title":"Epidemiology of infertility in China: a population-based study","volume":"125","author":"Zhou","year":"2018","journal-title":"BJOG"},{"key":"10.1016\/j.ejphar.2026.178639_bib34","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMra1810764","article-title":"Endometriosis","volume":"382","author":"Zondervan","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926001214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926001214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T02:56:55Z","timestamp":1786071415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926001214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"alternative-id":["S0014299926001214"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178639","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, pharmacokinetics, and sex hormone suppression of LY01021 versus relugolix: A single- and multiple-dose escalation study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178639"}}